Figure 1 from Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

<p>Duration of treatment and response with TRK-950 and representative antitumor activity in patients with cholangiocarcinoma. <b>A,</b> Duration of treatment and response with TRK-950. Each bar represents 1 patient. The length of the bar represents the duration of treatment with TRK-950. Treatment duration was defined as follows: (Date of Last Dose – Date of First Dose + 1), and was the period up to the date of the last dose. BOR, best overall response; ND, not detected; PD, progressive disease; missing, no samples to evaluate. <b>B,</b> Representative image of CAPRIN-1 expression in patients with cholangiocarcinoma. CAPRIN-1–IHC staining features observed in archival tumor specimens of cholangiocarcinoma. <b>C–F,</b> Representative antitumor activity in patients with cholangiocarcinoma. CT scans of the metastatic lung region for a patient receiving TRK-950 10 mg/kg. Images were taken (<b>C</b> and <b>D</b>) at baseline and (<b>E</b> and <b>F</b>) 177 days after TRK-950 treatment. <b>D</b> and <b>F</b> indicate enlarged regions.</p>